[go: up one dir, main page]

BR9700829A - Uso de interferon consensus humano para a produção de um medicamento - Google Patents

Uso de interferon consensus humano para a produção de um medicamento

Info

Publication number
BR9700829A
BR9700829A BR9700829A BR9700829A BR9700829A BR 9700829 A BR9700829 A BR 9700829A BR 9700829 A BR9700829 A BR 9700829A BR 9700829 A BR9700829 A BR 9700829A BR 9700829 A BR9700829 A BR 9700829A
Authority
BR
Brazil
Prior art keywords
drug
production
human consensus
consensus interferon
interferon
Prior art date
Application number
BR9700829A
Other languages
English (en)
Inventor
Michael Klein
Larry Blatt
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BR9700829A publication Critical patent/BR9700829A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9700829A 1996-02-05 1997-01-30 Uso de interferon consensus humano para a produção de um medicamento BR9700829A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/595,440 US5980884A (en) 1996-02-05 1996-02-05 Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon

Publications (1)

Publication Number Publication Date
BR9700829A true BR9700829A (pt) 1998-07-07

Family

ID=24383236

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9700829A BR9700829A (pt) 1996-02-05 1997-01-30 Uso de interferon consensus humano para a produção de um medicamento

Country Status (15)

Country Link
US (1) US5980884A (pt)
EP (1) EP0879059A1 (pt)
JP (1) JP2000504010A (pt)
KR (1) KR19990082084A (pt)
CN (1) CN1217660A (pt)
AU (1) AU1531897A (pt)
BR (1) BR9700829A (pt)
CZ (1) CZ231998A3 (pt)
EA (1) EA199800674A1 (pt)
HU (1) HUP9900929A3 (pt)
IL (1) IL125494A0 (pt)
NO (1) NO983410L (pt)
SK (1) SK101798A3 (pt)
WO (1) WO1997027866A1 (pt)
ZA (1) ZA97721B (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20012489B (en) * 1996-02-28 2001-07-25 Ifi Inst Farmacoterapico Italiano S P A Use of Natural Human α-Interferon
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
AU2002227252A1 (en) * 2000-12-01 2002-06-11 Cornell Research Foundation Animal model for flaviviridae infection
US20060035327A1 (en) * 2001-02-28 2006-02-16 Guangwen Wei Recombinant super-compound interferon and uses thereof
US20050079579A1 (en) * 2001-02-28 2005-04-14 Guangwen Wei Uses of spatial configuration to modulate protein function
CN1245215C (zh) * 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US8551469B2 (en) * 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
IL160882A0 (en) * 2001-09-28 2004-08-31 Intermune Inc Method for treating hepatitis c virus infection in treatment failure patients
PL369129A1 (en) * 2001-09-28 2005-04-18 Intermune, Inc. Method for treating hepatitis c virus infection in treatment failure patients
US7138376B2 (en) * 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
WO2003030613A2 (en) * 2001-10-05 2003-04-17 Intermune, Inc. Methods of treating liver fibrosis and hepatitis c virus infection
IL160965A0 (en) * 2001-10-05 2004-08-31 Intermune Inc Method of treating hepatitis virus infection with a multiphasic interferon delivery profile
AU2002346686A1 (en) * 2001-12-07 2003-06-23 Intermune, Inc. Compositions and method for treating hepatitis virus infection
NZ534811A (en) * 2002-02-14 2007-07-27 Pharmasset Inc Modified fluorinated nucleoside analogues
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
AU2003248748A1 (en) 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
MY140819A (en) 2002-06-28 2010-01-29 Idenix Caymans Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
US7824851B2 (en) 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
KR20050109918A (ko) 2002-12-12 2005-11-22 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드의 제조 방법
US20070077225A1 (en) * 2003-02-28 2007-04-05 Blatt Lawrence M Continuous delivery methods for treating hepatitis virus infection
AU2003225670A1 (en) * 2003-02-28 2004-09-28 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
CA2734052A1 (en) 2003-05-30 2005-01-13 Pharmasset, Inc. Modified fluorinated nucleoside analogues
US7585647B2 (en) * 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
PT1663110E (pt) * 2003-08-28 2014-03-13 Superlab Far East Ltd Utilizações de interferões com a estrutura espacial alterada
RS20110578A3 (en) 2003-10-14 2016-02-29 F. Hoffmann-La Roche Ltd MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
NZ548255A (en) 2004-02-02 2010-10-29 Ambrx Inc Modified human interferon polypeptides and their uses
CN1980657A (zh) 2004-05-05 2007-06-13 耶鲁大学 新颖的抗病毒赛菊宁黄质类似物
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
BRPI0515279A (pt) 2004-09-14 2008-07-15 Pharmasset Inc preparação de ribofuranosil pirimidinas e purinas 2'fluoro-2'-alquil- substituìdas ou outras opcionalmente substituìdas e seus derivados
US20080124302A1 (en) * 2005-03-09 2008-05-29 Guangwen Wei Uses of Recombinant Super-Compound Interferons
KR101294467B1 (ko) 2005-07-25 2013-09-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 거대고리형 억제제
DE602006019323D1 (de) 2005-10-11 2011-02-10 Intermune Inc Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
WO2007075876A2 (en) 2005-12-23 2007-07-05 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010075554A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Synthesis of purine nucleosides
US8716262B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2376514A2 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
TWI583692B (zh) * 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
CA2764759A1 (en) * 2009-06-09 2010-12-16 Defyrus, Inc. Administration of interferon for prophylaxis against or treatment of pathogenic infection
EP2459211A1 (en) 2009-07-31 2012-06-06 Medtronic, Inc. Continuous subcutaneous administration of interferon- to hepatitis c infected patients
RS54368B1 (sr) 2010-03-31 2016-04-28 Gilead Pharmasset Llc Kristalni (s)-izopropil 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-diokso-3,4-dihidropirimidin-1-(2h)-il)-4-fluoro-3-hidroksi-4-metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino)propanoat
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
CN102711871A (zh) 2010-06-16 2012-10-03 麦德托尼克公司 用于稳定药物递送装置中的药物的阻尼系统
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
EA201490837A1 (ru) 2011-10-21 2014-11-28 Эббви Инк. Способы лечения hcv, включающие по меньшей мере два противовирусных агента прямого действия, рибавирин, но не интерферон
AU2013201532B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
TWI726291B (zh) 2013-01-07 2021-05-01 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
SG11201600919UA (en) 2013-08-27 2016-03-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect

Also Published As

Publication number Publication date
ZA97721B (en) 1997-08-01
HUP9900929A3 (en) 1999-11-29
CN1217660A (zh) 1999-05-26
IL125494A0 (en) 1999-03-12
EA199800674A1 (ru) 1999-02-25
NO983410L (no) 1998-10-05
AU1531897A (en) 1997-08-22
HUP9900929A2 (hu) 1999-07-28
US5980884A (en) 1999-11-09
WO1997027866A1 (en) 1997-08-07
JP2000504010A (ja) 2000-04-04
EP0879059A1 (en) 1998-11-25
KR19990082084A (ko) 1999-11-15
NO983410D0 (no) 1998-07-23
CZ231998A3 (cs) 1999-03-17
SK101798A3 (en) 2000-03-13

Similar Documents

Publication Publication Date Title
BR9700829A (pt) Uso de interferon consensus humano para a produção de um medicamento
CY2007001I2 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
PT864327E (pt) Utilizacao de derivados de pirimidina para a preparacao de um medicamento para a prevencao do cancro
FI952932A0 (fi) Monomeeriset insuliinianalogivalmisteet
DK0941103T3 (da) Farmaceutisk præparat til behandling af diabetes
DE69525148D1 (de) Pharmazeutische formulierung
NO954486D0 (no) Farmasöytiske formuleringsgrunnlag
DE69513671D1 (de) Arzneimittel
MA26549A1 (fr) Medicaments
ID24654A (id) Formulasi farmasi omeprazola
BR9701673A (pt) Disposição para a aplicação de um líquido medicinal
NO982874D0 (no) Farmas°ytiske preparater med vitamin D-analoger
BR9601193A (pt) Vacina de múltiplos componentes e processos para preparar e administrar a vacina
DK0879054T3 (da) Anvendelse af pyrrolidionderivater til fremstilling af medikamenter til behandling af narkotikamisbrug
FI973230A0 (fi) Uusi farmaseuttinen formulaatio
FI951155A7 (fi) Farmaseuttinen valmiste
HUP9904181A3 (en) Sufrace-stabilised pharmaceutical preparation for application on the skin
FI953720A0 (fi) Neurotensiiniantagonistien käyttö diureettietan lääkkeiden valmistamiseksi
EE200000401A (et) Farmatseutilise preparaadi valmistamismeetod
NO942228D0 (no) Ipsapiron-legemiddeltilberedning
LV11966A (lv) Pretiekaisumu lidzeklis arigai lietosanai
DE69810442D1 (de) Anordnung zur verabreichung von medikamenten
BR9603673A (pt) Preparado de combinação farmacêutica compreendendo cetoprofeno
IT1295067B1 (it) Uso di arsenico per preparare un medicamento per il trattamento della sindrome premestruale
ATA77096A (de) Pharmazeutische präparation

Legal Events

Date Code Title Description
FB34 Technical and formal requirements: requirement - article 34 of industrial property law
B11T Dismissal of application maintained [chapter 11.20 patent gazette]